Literature DB >> 2998818

DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity.

J T Haskins, J A Moyer, E A Muth, E B Sigg.   

Abstract

Wy-45,030 and Wy-45,881 block the uptake of norepinephrine and serotonin in rat brain synaptosomal preparations and share several in vivo and in vitro effects with known tricyclic antidepressants. To further characterize their activity, these compounds were compared to desipramine and ciramadol in electrophysiological studies of their acute effects on noradrenergic neuronal activity. All four compounds inhibited locus coeruleus neuronal activity with a rank order of potency of desipramine greater than Wy-45,881 greater than Wy-45,030 greater than ciramadol. Administration of the alpha-adrenergic blocking drug, piperoxane, increased locus coeruleus firing rate after desipramine, Wy-45,030 and Wy-45-881. Pretreatment with naloxone prevented the reduction in locus coeruleus impulse flow observed after ciramadol administration but had no effect on the inhibition produced by Wy-45,030. Wy-45,030 and Wy-45,881, like classical antidepressants, appear to inhibit locus coeruleus neuronal firing by potentiating neuroinhibitory transmission of locus coeruleus neurons by blocking the uptake of norepinephrine into presynaptic terminals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998818     DOI: 10.1016/0014-2999(85)90684-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 2.  The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.

Authors:  Eleni Pitsillou; Sarah M Bresnehan; Evan A Kagarakis; Stevano J Wijoyo; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

3.  Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.

Authors:  M Hermann; M Hendset; K Fosaas; M Hjerpset; H Refsum
Journal:  Eur J Clin Pharmacol       Date:  2008-01-23       Impact factor: 2.953

Review 4.  Venlafaxine. A review of its pharmacology and therapeutic potential in depression.

Authors:  S M Holliday; P Benfield
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

5.  Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.

Authors:  Jingjing Zhou; Xiao Wang; Lei Feng; Le Xiao; Rui Yang; Xuequan Zhu; Hui Shi; Yongdong Hu; Runsen Chen; Philip Boyce; Gang Wang
Journal:  BMC Psychiatry       Date:  2021-05-19       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.